The strain has a mutation called N501Y - a slight alteration on one spot of the spike protein that forces more aggressive contagiousness. Most vaccines available around the world train the body to recognize that spike protein and fight it.
Pfizer teamed up with researchers from the University of Texas at Galveston's medical department for laboratory tests to see if the mutation affected the vaccine's ability to do so.
According to Veran, by the end of January, France will have begun vaccinating people aged 75 and above who are living at home.
The country initially received 500,000 doses of the vaccine developed by Pfizer Inc and Germany’s BioNTech SE and was due to receive an additional 500,000 per week.